ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
OTUD6A-Mediated Deubiquitination of PRDX1 Protects Against Oral Ulcer by Restoring Mitochondrial Function.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Oral ulcers (OU), as the most highly prevalent and recurrent oral mucosal lesion, have an unclear pathogenesis that hampers the development of effective treatments. While emerging evidence suggests that deubiquitinating enzymes (DUBs) may play a role in oral diseases, their functions in OU remain unclear. In this study, we screened the expression of DUBs in tongue tissues from mice with OU and identified OTU domain-containing protein 6A (OTUD6A) as the most substantially downregulated DUB during OU progression. The functional studies demonstrated that OTUD6A deficiency exacerbated OU pathology in mice and, correspondingly, suppressed proliferation and migration while promoting apoptosis of human oral keratinocytes (HOKs). Mechanistic investigations revealed that OTUD6A directly bound to peroxiredoxin-1 (PRDX1) and cleaved its K48-linked polyubiquitin chains at lysine 136 site (K136) via the catalytic residue C152, thereby stabilizing PRDX1 in HOKs. Loss of OTUD6A led to PRDX1 degradation, which enhanced mitochondrial oxidative stress and dysfunction, ultimately impairing HOKs function, while OTUD6A overexpression rescued HOKs malfunction. Importantly, local administration of recombinant OTUD6A protein significantly accelerated OU healing in mice. Collectively, these results identify a new OTUD6A-PRDX1 axis in OU pathology and present OTUD6A as a promising therapeutic target for OU.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.